One Dose of Psychedelic DMT Significantly Alleviates Depression Symptoms

Recent research demonstrates that a single dose of the hallucinogen dimethyltryptamine (DMT) yields rapid and enduring improvements in symptoms of depression.

DMT, an exceptionally potent hallucinogen sourced from various plants globally, is under strict international regulation, with the United Nations categorizing it as a substance with a notable potential for abuse and no recognized medical use.

Nonetheless, observational studies indicate that DMT and other psychedelics may offer therapeutic benefits to individuals grappling with severe mental health disorders, particularly those unresponsive to conventional interventions.

In a recent study led by David Elizzo at Imperial College London, researchers examined 34 participants suffering from moderate to severe depression, each having endured this condition for an average of 10 years while unsuccessfully trying at least two standard treatment methods.

Accompanied by therapeutic support, half of the participants received a substantial dose of 21.5 milligrams of DMT intravenously over a duration of 10 minutes, while the remainder were administered a placebo.

All participants completed a depression assessment questionnaire before the study commenced, revealing an average 7.4-point decrease in depression scores among the DMT group two weeks post-infusion compared to the placebo group. This decrease remained consistent for up to 6 months in certain participants.

Furthermore, all participants had the option to access a second dose of DMT, managed by a therapist. The findings suggest no significant enhancement in outcomes beyond the initial treatment, indicating a single dose may suffice for sustained benefits.

Regarding safety, side effects were reported as mild, with occasional instances of temporary anxiety, nausea, and localized pain at the injection site.

“Our findings indicate that a single DMT experience lasting just 25 minutes is safe, well-tolerated, and correlates with substantial, long-lasting improvements in depression,” asserts Elizzo. “Notably, these early indications closely resemble results from trials involving long-acting psychedelics such as psilocybin.” Additionally, the brevity of the DMT experience could potentially alleviate treatment costs.

However, the inherent nature of psychedelic drug consumption means participants can often distinguish between the placebo and DMT groups, suggesting that outcomes may reflect both the pharmacological effects of DMT and participants’ expectations.

The researchers found that the intensity of mystical experiences reported approximately 25 minutes after DMT administration was linked to the degree of therapeutic benefit. “Participants who reported feelings of connection, significant emotional shifts, and profound, indescribable experiences were more likely to report increased benefits,” noted team members, including Tommaso Barba from Imperial.

While the exact mechanisms by which psychedelics like DMT alleviate depression remain unclear, some studies imply that they may offer a transient period of neuroplasticity, facilitating new neuronal connections and reducing inflammation associated with poor mental health.

Rick Strassman, a pioneer in psychedelic research, emphasizes the necessity for caution. Although DMT experiences are shorter than those of psilocybin or LSD, the disorienting effects can be greater and demand careful preparation and monitoring.

Elizzo and his team advocate for further investigation into a modified version of DMT called HLP004, aimed at anxiolytic properties. Concurrently, the similar compound 5-MeO-DMT is undergoing advanced trials for depression treatment. Notably, promising results from AtaiBeckley indicate expedited development of drug candidates for treatment-resistant depression, pushing towards potential approval in the U.S.